FrancophonIA/ELRC3.0 huggingface dataset:
English: Triumeq does not cure HIV infection or AIDS, but it may delay the damage to the immune system and the development of infections and diseases associated with AIDS.
Estonian: Triumeq ei ravi HIV-nakkust ega AIDSi välja, kuid võib edasi lükata immuunsüsteemi kahjustumise ning AIDSiga seostatavate nakkuste ja haiguste tekke.
English: The Agency's Committee for Medicinal Products for Human Use (CHMP) decided that Triumeq's benefits are greater than its risks and recommended that it be approved for use in the EU.
Estonian: Inimravimite komitee otsustas, et Triumeqi kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas ravimi kasutamise Euroopa Liidus heaks kiita.
English: Triumeq is available as tablets (50 mg dolutegravir / 600 mg abacavir /300 mg lamivudine) and the recommended dose is one tablet a day, taken with or without food.
Estonian: Triumeqi turustatakse tablettidena (50 mg dolutegraviiri / 600 mg abakaviiri / 300 mg lamivudiini) ja soovitatav annus on üks tablett üks kord ööpäevas koos toiduga või ilma.
English: Triumeq reduces the amount of HIV in the blood and keeps it at a low level.
Estonian: Triumeq vähendab HIVi kogust veres ja hoiab selle sisalduse väikese.
English: The CHMP concluded that the medicine had demonstrated its effectiveness in previously untreated patients, and that similar benefits are expected in patients who have received previous treatment.
Estonian: Inimravimite komitee jõudis järeldusele, et ravimi efektiivsus on tõendatud varem ravimata patsientidel ja et sarnast kasulikkust eeldatakse ka eelnevalt ravi saanud patsientidel.
English: What is Triumeq and what is it used for?
Estonian: Mis on Triumeq ja milleks seda kasutatakse?
English: The combination of dolutegravir, abacavir and lamivudine (as found in Triumeq) was evaluated in one main study involving 833 previously untreated patients.
Estonian: Dolutegraviiri, abakaviiri ja lamivudiini kombinatsiooni (nagu need esinevad Triumeqis) hinnati ühes põhiuuringus, milles osales 833 varem ravimata patsienti.
English: All three active substances in Triumeq are already available in the European Union (EU) as singlecomponent medicines: abacavir has been authorised as Ziagen since 1999, lamivudine as Epivir since 1996, and dolutegravir as Tivicay since January 2014.
Estonian: Triumeqi kõiki kolme toimeainet juba turustatakse Euroopa Liidus ühekomponentsete ravimitena: abakaviiril on müügiluba ravimina Ziagen alates 1999. aastast, lamivudiinil ravimina Epivir alates 1996. aastast ja dolutegraviiril ravimina Tivicay alates 2014. aasta jaanuarist.
English: Patients with this gene are at an increased risk of having an allergic reaction to abacavir, so they should not take Triumeq.
Estonian: Patsientidel, kes on selle geeni kandjad, on suurem oht abakaviiriga seotud ülitundlikkusreaktsiooni tekkeks, seega ei tohi nad Triumeqit võtta.
English: This is a summary of the European public assessment report (EPAR) for Triumeq.
Estonian: See on ravimi Triumeq Euroopa avaliku hindamisaruande kokkuvõte.
English: Before starting treatment with Triumeq, all patients should have a test to find out if they have a gene called ‘HLA-B (type 5701)'.
Estonian: Enne Triumeqiga ravi alustamist tuleb kõigil patsientidel määrata geeni HLA-B (tüüp 5701) kandlus.
English: The CHMP also considered the fact that Triumeq can be taken with or without food as an additional advantage compared with other similar medicines which have to be taken strictly either with food or on an empty stomach.
Estonian: Inimravimite komitee pidas lisaeeliseks ka asjaolu, et Triumeqit võib manustada kas koos toiduga või ilma, võrreldes teiste sarnaste ravimitega, mida tuleb manustada kindlasti kas koos toiduga või tühja kõhuga.
English: Triumeq dolutegravir / abacavir / lamivudine
Estonian: Triumeq dolutegraviir/abakaviir/lamivudiin
English: In patients taking some of the components of Triumeq, certain serious side effects have been seen including hypersensitivity (allergic).
Estonian: Patsientidel, kes manustavad mõnda Triumeqi komponentidest, on täheldatud teatavaid raskeid kõrvalnähte, sealhulgas ülitundlikkust (allergia).
English: The main measure of effectiveness was the response rate, which was the proportion of patients with a reduction of the levels of virus in the blood (viral load) to fewer than 50 copies of HIV RNA per ml.
Estonian: Efektiivsuse põhinäitaja oli ravivastus, mis näitab nende patsientide osakaalu, kelle vere viirusesisaldus vähenes alla 50 HIV RNA koopia/ml.
English: Patients were either given the Triumeq combination or a different three-drug combination (Atripla) that did not include an integrase inhibitor.
Estonian: Patsientidele manustati kas Triumeqi kombinatsiooni või teistsugust kolme ravimi kombinatsiooni (Atripla), mis ei sisaldanud integraasi inhibiitorit.
English: This is an antiviral medicine that blocks an enzyme called integrase that is needed by the HIV virus to make new copies of itself in the body.
Estonian: See on viirusevastane ravim, mis blokeerib ensüümi integraas, mida HI-viirus vajab viirusest uute koopiate tegemiseks organismis.
English: The CHMP also noted that giving the combination of dolutegravir, abacavir and lamivudine as a single tablet is an additional treatment option for patients with HIV infection and without the HLA-B (type 5701) gene.
Estonian: Inimravimite komitee märkis ka, et dolutegraviiri, abakaviiri ja lamivudiini kombinatsiooni manustamine ühe tabletina on ravi lisavõimalus nende HIV-nakkusega patsientide jaoks, kes ei ole geeni HLA-B (tüüp 5701) kandjad.
English: The other two active substances, abacavir and lamivudine, are nucleoside reversetranscriptase inhibitors (NRTIs).
Estonian: Teised kaks toimeainet, abakaviir ja lamivudiin, on nukleosiidsed pöördtranskriptaasi inhibiitorid (NRTId).
English: Why is Triumeq approved?
Estonian: Miks Triumeq heaks kiideti?
English: Regarding Triumeq's safety profile, this was expected to be similar to the safety profile of the single components and comparable to that of other HIV treatments.
Estonian: Triumeqi ohutusprofiili kohta leiti, et see on eeldatavasti sarnane üksikute komponentide ohutusprofiiliga ja võrreldav HIV-nakkuse muude ravimite ohutusprofiiliga.
English: It is not intended to provide practical advice on how to use Triumeq.
Estonian: Hindamisaruandes ei anta Triumeqi kasutamise praktilisi nõuandeid.
English: The most common side effects with Triumeq (which may affect more than 1 in 10 people) are insomnia (difficulty sleeping), headache, nausea (feeling sick), diarrhoea and fatigue (tiredness).
Estonian: Triumeqi kõige sagedamad kõrvalnähud (võivad esineda enam kui 1 patsiendil 10st) on unetus, peavalu, iiveldus, kõhulahtisus ja väsimus.
English: What are the risks associated with Triumeq?
Estonian: Mis riskid Triumeqiga kaasnevad?
English: Triumeq contains three active substances: dolutegravir, abacavir and lamivudine.
Estonian: Triumeq sisaldab kolme toimeainet: dolutegraviir, abakaviir ja lamivudiin.
English: The combination of abacavir and lamivudine has been authorised as Kivexa since 2004.
Estonian: Abakaviiri ja lamivudiini kombinatsioonil on müügiluba ravimina Kivexa alates 2004. aastast.
English: The company also looked at the way Triumeq was absorbed in the body in comparison with two separate tablets (dolutegravir and abacavir/lamivudine) containing the three medicines that make it up.
Estonian: Ettevõte uuris ka Triumeqi imendumist organismis võrreldes kahe eraldi tabletiga (dolutegraviir ja abakaviir/lamivudiin), mis sisaldavad Triumeqi kolme toimeainet.
English: Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Triumeq, including the appropriate precautions to be followed by healthcare professionals and patients.
Estonian: Selle alusel lisati Triumeqi omaduste kokkuvõttesse ja pakendi infolehele ravimi ohutusteave, kus on ka tervishoiuspetsialistide ja patsientide võetavad meetmed.
English: One of the active substances in Triumeq, dolutegravir, is an integrase inhibitor.
Estonian: Triumeqi üks toimeainetest, dolutegraviir, on integraasi inhibiitor.
English: For practical information about using Triumeq, patients should read the package leaflet or contact their doctor or pharmacist.
Estonian: Kui vajate Triumeqi kasutamise praktilisi nõuandeid, lugege pakendi infolehte või pöörduge oma arsti või apteekri poole.
English: Triumeq is an antiviral medicine used to treat patients with human immunodeficiency virus (HIV), the virus that causes acquired immunodeficiency syndrome (AIDS).
Estonian: Triumeq on viirusevastane ravim, mida kasutatakse omandatud immuunpuudulikkuse sündroomi (AIDS) põhjustava inimese immuunpuudulikkuse viirusega (HIV) patsientide raviks.
English: How does Triumeq work?
Estonian: Kuidas Triumeq toimib?
English: For more information about treatment with Triumeq, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Estonian: Kui vajate Triumeqiga toimuva ravi kohta lisateavet, lugege palun pakendi infolehte (mis on samuti Euroopa avaliku hindamisaruande osa) või pöörduge oma arsti või apteekri poole.
English: Triumeq can only be obtained with a prescription and treatment should be prescribed by a doctor who is experienced in managing HIV infections.
Estonian: Triumeq on retseptiravim ja ravi tohib määrata HIV-nakkuse ravikogemusega arst.
English: In addition, the company that markets Triumeq will provide educational material for healthcare professionals expected to prescribe Triumeq that addresses the risk of abacavir-associated hypersensitivity.
Estonian: Lisaks annab Triumeqit turustav ettevõte teabematerjalid Triumeqit määravatele tervishoiutöötajatele.
English: How is Triumeq used?
Estonian: Kuidas Triumeqit kasutatakse?
English: For the full list of restrictions with Triumeq, see the package leaflet.
Estonian: Triumeqi piirangute täielik loetelu on pakendi infolehel.
English: What benefits of Triumeq have been shown in studies?
Estonian: Milles seisneb uuringute põhjal Triumeqi kasulikkus?
English: Triumeq must not be used together with dofetilide, a medicine used to control cardiac arrhythmia (unstable heartbeat).
Estonian: Triumeqit ei tohi kasutada koos südame rütmihäirete (ebastabiilne pulss) raviks kasutatava dofetiliidiga.
English: For the full list of all side effects reported with Triumeq, see the package leaflet.
Estonian: Triumeqi kohta teatatud kõrvalnähtude täielik loetelu on pakendi infolehel.
English: The full EPAR for Macugen can be found on the Agency's website ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
Estonian: Euroopa avaliku hindamisaruande täistekst Macugeni kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
English: The European Commission granted a marketing authorisation valid throughout the European Union for Macugen on 31 January 2006.
Estonian: Euroopa Komisjon andis Macugeni müügiloa, mis kehtib kogu Euroopa Liidu territooriumil, 31. jaanuaril
English: What measures are being taken to ensure the safe use of Macugen?
Estonian: Mis meetmeid võetakse, et tagada Macugeni kasutamise ohutus?
English: Other information about Macugen
Estonian: Muu teave Macugeni kohta
English: Macugen has been studied in two main clinical studies involving a total of 1,190 patients and lasting up to two years.
Estonian: Macugeni uuriti kahes kliinilises põhiuuringus, milles osales ligikaudu 1190 patsienti ja mis kestsid kuni 2 aastat.
English: EPAR summary for the public pegaptanib
Estonian: Kokkuvõte üldsusele pegaptaniib
English: Before each injection, a local anaesthetic will be given to reduce or prevent any pain from the injection.
Estonian: Enne iga süsti manustatakse valu vähendamiseks või ennetamiseks paikset anesteetikumi.
English: The CHMP decided that Macugen's benefits are greater than its risks and recommended that it be given marketing authorisation.
Estonian: Inimravimite komitee otsustas, et Macugeni kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda ravimi müügiloa.
English: If, after two injections, no benefit is seen on the patient's eyesight, the treatment should be stopped or withheld.
Estonian: Kui pärast kaht süsti patsiendi nägemine ei parane, tuleb ravi peatada.
English: It is important to treat these types of conditions as soon as possible.
Estonian: Neid seisundeid peab ravima otsekohe.
English: The macula provides central vision that is needed to see detail for everyday tasks such as driving, reading and recognising faces.
Estonian: Kollastähn annab kujutise nägemisvälja keskel, mida on vaja teravaks nägemiseks tavategevuste korral, näiteks autojuhtimisel, lugemisel ja nägude äratundmisel.
English: The patients were given either Macugen (0.3 mg, 1 mg or 3 mg) or a ‘sham' injection.
Estonian: Patsientidele süstiti kas Macugeni (0,3 mg, 1 mg või 3 mg) või tehti näiline süst.
English: The main measure of effectiveness was the proportion of patients losing less than 15 letters in a standard eye test.
Estonian: Efektiivsuse põhinäitaja oli nende patsientide osakaal, kelle nägemine halvenes standardse silmakontrollitabeli põhjal vähem kui 15 tähte.
English: This is a summary of the European public assessment report (EPAR) for Macugen.
Estonian: See on ravimi Macugen Euroopa avaliku hindamisaruande kokkuvõte.
English: An aptamer is a single strand of molecules called nucleotides that has been designed to attach to a specific molecule in the body.
Estonian: Aptameer on nukleotiid ehk teatud üheahelaline molekul, mis on ette nähtud seonduma organismi teatud struktuuriga.
English: This reduces the growth of blood vessels in the eye and controls the leakage and swelling.
Estonian: See vähendab veresoonte kasvamist silma sees ning piirab vedeliku eritumist ja turset.
English: The 3 mg dose did not bring any additional benefit.
Estonian: 3 mg annuse täiendav kasulik mõju puudus.
English: For more information about treatment with Macugen, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Estonian: Kui vajate Macugeniga toimuva ravi kohta lisateavet, lugege palun pakendi infolehte (mis on samuti Euroopa avaliku hindamisaruande osa) või pöörduge oma arsti või apteekri poole.
English: Macugen is given as one injection of 0.3 mg into the affected eye every six weeks.
Estonian: Macugeni süstitakse haigesse silma ühe 0,3 mg annusena iga 6 nädala tagant.
English: This improvement lasted for two years in patients who were given Macugen.
Estonian: Macugeni saanud patsientidel püsis paranemine 2 aastat.
English: Macugen must not be used in people who are hypersensitive (allergic) to pegaptanib or any of the other ingredients.
Estonian: Macugeni ei tohi kasutada patsiendid, kes on pegaptaniibi või selle ravimi mis tahes muu koostisaine suhtes ülitundlikud (allergilised).
English: It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Macugen.
Estonian: Selles selgitatakse, kuidas inimravimite komitee hindas ravimit ja otsustas toetada müügiloa andmist; samuti esitatakse komitee soovitused, kuidas ravimit kasutada.
English: What is Macugen?
Estonian: Mis on Macugen?
English: This is a procedure that is similar to a Macugen injection, but with no Macugen and no needle, in which a syringe is pressed against the eye but nothing is actually injected.
Estonian: Näiline süst sarnaneb Macugeni süstimisega, kuid ilma ravimita ja nõelata: süstal surutakse vastu silma, kuid süstimist tegelikult ei toimu.
English: For the full list of all side effects reported with Macugen, see the package leaflet.
Estonian: Macugeni kohta teatatud kõrvalnähtude täielik loetelu on pakendi infolehel.
English: The most common side effects with Macugen (seen in more than 1 patient in 10) are anterior chamber inflammation (inflammation of the front part of the eye), pain in the eye, raised intraocular pressure (increased pressure inside the eye), punctate keratitis (small marks on the eye surface) and vitreous floaters or opacities (small particles or spots in the vision).
Estonian: Macugeni kõige sagedamad kõrvalnähud (esinenud enam kui 1 patsiendil 10st) on sarvkesta põletik, silmavalu, silma suurenenud siserõhk, punktaatkeratiit (väikesed täpid sarvkestal) ja klaaskehas hõljuvad objektid (laigud vaateväljas).
English: What is the risk associated with Macugen?
Estonian: Mis riskid Macugeniga kaasnevad?
English: Antibiotic eye drops may also be given before and after the Macugen injection, to prevent eye infection.
Estonian: Silmanakkuse ennetamiseks võidakse enne ja pärast Macugeni süstimist manustada ka antibiootilisi silmatilku.
English: In the body, VEGF is involved in the growth of blood vessels and in making them more permeable.
Estonian: VEGF reguleerib veresoonte kasvu ja muudab need läbilaskvamaks.
English: Macugen is used to treat adults with the ‘wet' form of age-related macular degeneration (AMD).
Estonian: Macugeni kasutatakse vanusega seotud makuladegeneratsiooni (AMD) märja vormi raviks täiskasvanutel.
English: The pre-filled syringe contains more than the recommended dose, therefore when preparing the injection, the doctor must expel a certain volume and ensure the injection of the correct dose.
Estonian: Eeltäidetud süstlas on ravimit soovitatavast annusest rohkem, seetõttu peab arst süsti ettevalmistamisel liigse koguse süstlast välja suruma.
English: Why has Macugen been approved?
Estonian: Miks Macugen heaks kiideti?
English: It must not be used in patients who have or are thought to have ocular or periocular infections (infections in or around the eyes).
Estonian: Seda ei tohi kasutada patsiendid, kellel on silma- või silmaümbruse infektsioonid või selliste infektsioonide kahtlus.
English: As Macugen when given by intravitreal injection can raise the pressure and cause bleeding within the eye, patients should be appropriately monitored after each injection.
Estonian: Silma sisse süstitav Macugen võib suurendada silma siserõhku ja tekitada silmasisest verejooksu, mistõttu tuleb patsiente pärast iga süsti jälgida.
English: Pegaptanib injected into the eye blocks VEGF.
Estonian: Pegaptaniibi süstimine silma blokeerib VEGF-i.
English: Macugen should only be given by an ophthalmologist (eye specialist) who is experienced in giving intravitreal injections (injections into the vitreous humour, the jelly-like fluid in the eye).
Estonian: Macugeni tohib manustada üksnes silmaarst, kellel on intravitreaalsete süstide (silmasisesed süstid ehk süstid silma klaaskehasse) tegemise kogemus.
English: The symptoms of these conditions and instructions about what to do if a patient has these symptoms are explained in the package leaflet.
Estonian: Nende seisundite sümptomite ja ravi kirjeldus on pakendi infolehel.
English: After one year of treatment, about 70% of the patients treated with Macugen 0.3 and 1 mg lost less than 15 letters in the eye test compared with about 55% of those who received the sham injection.
Estonian: Pärast üheaastast ravi oli nende patsientide osakaal, kelle nägemine halvenes standardse silmakontrollitabeli põhjal vähem kui 15 tähte, Macugeni annuses 0,3 mg ja 1 mg saanute seas ligikaudu 70% ja näilise süsti saanute seas ligikaudu 55%.
English: The CHMP noted that in patients with wet AMD Macugen 0.3 mg had similar effects on vision loss as Macugen 1 mg, therefore the lower dose was selected for approval.
Estonian: Inimravimite komitee märkis, et Macugeni annuste 0,3 mg ja 1 mg mõju AMD märja vormiga patsientide nägemiskaotusele oli sarnane, ning seepärast kiideti heaks väiksem annus.
English: Pegaptanib has been designed to attach to and block a protein called vascular endothelial growth factor (VEGF).
Estonian: Pegaptaniib on ette nähtud seonduma endoteeli kasvuteguriga (VEGF), et see blokeerida.
English: Macugen is a solution for injection into the eye that contains the active substance pegaptanib.
Estonian: Macugen on silma süstitav lahus, mille toimeaine on pegaptaniib.
English: The active substance in Macugen, pegaptanib, is an ‘aptamer'.
Estonian: Macugeni toimeaine pegaptaniib on aptameer.
English: The wet form of AMD is caused by the abnormal growth of blood vessels under the macula, which may leak fluid and blood and cause swelling.
Estonian: AMD märga vormi põhjustab ebanormaalsete veresoonte moodustumine kollastähni all, nendest võib erituda vedelikku ja verd ning see võib tekitada turse, mis põhjustab nägemise järkjärgulise kaotuse nägemisvälja keskel.
English: Sometimes, endophthalmitis (an infection inside the eye), vitreous haemorrhage (bleeding into the eye) and retinal damage can occur after Macugen treatment.
Estonian: Mõnikord võib pärast ravi Macugeniga tekkida endoftalmiit (silmasisemuse põletik), klaaskeha veritsemine (silmasisene verejooks) ja võrkkestakahjustus.
English: It is available as a prefilled syringe.
Estonian: Seda turustatakse eeltäidetud süstaldes.
English: What is Macugen used for?
Estonian: Milleks Macugeni kasutatakse?
English: How is Macugen used?
Estonian: Kuidas Macugeni kasutatakse?
English: How has Macugen been studied?
Estonian: Kuidas Macugeni uuriti?
English: What benefit has Macugen shown during the studies?
Estonian: Milles seisneb uuringute põhjal Macugeni kasulikkus?
English: This disease affects the central part of the retina called the macula at the back of the eye.
Estonian: See haigus kahjustab võrkkesta keskosa (kollastähni) silma tagaosas.
English: The company that makes Macugen will provide educational material for doctors (to minimise the risks associated with the injection in the eye) and for patients (so they can recognise any serious side effects, and know when to seek urgent attention from their doctor).
Estonian: Arstide teabematerjal selgitab, kuidas minimeerida silmasisese süsti infektsiooniriski; patsientide teabematerjal kirjeldab raskeid kõrvalnähte ning seda, millal on vaja otsekohe pöörduda arsti poole.
English: How does Macugen work?
Estonian: Kuidas Macugen toimib?
English: The Marketing Authorisation was subsequently renewed.
Estonian: Hiljem müügiluba pikendati.
English: Safety of the product was satisfactorily demonstrated.
Estonian: Ravimi ohutus on piisavalt tõendatud.
English: Neocolipor contains inactivated strains of E. coli expressing the adhesins F4ab (K88ab), F4ac (K88ac), F4ad (|K88 ad) F5 (K99) F6 (987P) and F41.
Estonian: Neocolipor sisaldab bakteri E. coli inaktiveeritud tüvesid, milles on ekspresseerunud adhesiinid F4ab (K88ab), F4ac (K88ac), F4ad (|K88 ad), F5 (K99), F6 (987P) ja F41.
English: The results presented showed statistical significance between vaccinates and non-vaccinates and thus demonstrated the efficacy of the vaccine.
Estonian: Tulemused näitasid vaktsineeritud ja vaktsineerimata loomade vahel olulisi statistilisi erinevusi ning seega tõendasid vaktsiini tõhusust.
English: The vaccine is given by intramuscular injection.
Estonian: Vaktsiini manustatakse intramuskulaarse süstina.
English: Vaccination may cause a slight rise in the animal's body temperature (less than 1.5°C during a maximum period of 24 hours).
Estonian: Vaktsineerimine võib põhjustada looma kehatemperatuuri kerget tõusu (vähem kui 1,5 °C maksimaalselt 24 tunni jooksul).
English: The European Commission granted a marketing authorisation, valid throughout the European Union, for Neocolipor to Mérial on 9 August 2002.
Estonian: Euroopa Komisjon andis Neocolipori müügiloa, mis kehtib kogu Euroopa Liidu territooriumil, ettevõttele Mérial 9. augustil 2002.
English: Zero days (the vaccine does not contain any ingredients that are likely to pose a risk for consumers of vaccinated animals at the recommended dose).
Estonian: Null päeva (vaktsiin ei sisalda koostisaineid, mis võiksid vaktsiini soovitatud annuses kasutamisel ohustada vaktsineeritud loomade liha toiduks tarbijaid).
English: EUROPEAN PUBLIC ASSESSMENT REPORT (EPAR) NEOCOLIPOR EPAR summary for the public
Estonian: EUROOPA AVALIK HINDAMISARUANNE NEOCOLIPOR Kokkuvõte üldsusele
English: In the case of accidental self injection, seek medical advice immediately and show the package insert or label to a physician.
Estonian: Juhusliku enesesüstimise korral tuleb pöörduda kohe arsti poole ja näidata talle pakendi infolehte või etiketti.